Relive the excitement of the Patriots’ path to their fourth Super Bowl Championship with “Pumped”, a special commemorative book from The Boston Globe. Order now.

Vertex CF drug cleared in Australia

Kalydeco’s the first drug for the underlying cause of CF in people with a particular mutation.

Kalydeco’s the first drug for the underlying cause of CF in people with a particular mutation.

Continue reading below

Cambridge-based Vertex Pharmaceuticals Inc.’s Kalydeco drug for cystic fibrosis was approved by Australian regulators. Kalydeco, cleared by US regulators in February 2012, targets the cause of the disease in about 4 percent of the US patient population — those with a specific genetic mutation — helping them produce mucus to absorb and digest food. Life-threatening CF affects about 70,000 people worldwide. In April, investors bid up Vertex shares to a record high after clinical data appeared to dramatically improve the prospects of Vertex’s plan to build a portfolio of CF drugs.

Loading comments...

Wake up with today's top stories.

Want each day's news headlines delivered fresh to your
inbox every morning? Just connect with us
in one of the following ways:
or
Please enter a valid email
BostonGlobe.com will never post anything without asking. Privacy Policy
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com